Joseph Catanzaro
Stock Analyst at Mizuho
(3.53)
# 911
Out of 5,116 analysts
103
Total ratings
43.53%
Success rate
8.45%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $18.37 | +112.30% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $29.48 | +73.00% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $16.80 | +7.14% | 1 | Dec 18, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $53 | $32.94 | +60.90% | 1 | Dec 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $81 → $120 | $81.32 | +47.57% | 2 | Dec 11, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $24 → $30 | $19.30 | +55.44% | 4 | Dec 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $90 | $80.75 | +11.46% | 3 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $26.38 | +81.96% | 1 | Oct 21, 2025 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $105 | $77.32 | +35.80% | 1 | Oct 21, 2025 | |
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.14 | +133.64% | 5 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2.5 → $5 | $4.39 | +13.90% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $2.85 | +110.53% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $18.31 | +145.77% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $84 | $96.92 | -13.33% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $124.70 | -11.79% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $46.24 | -17.82% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $21.03 | -28.67% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $68.87 | -23.04% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $3.17 | +215.46% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.32 | +1,339.39% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $10.22 | +85.91% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.59 | +479.15% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $16.87 | +113.40% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $9.45 | +323.28% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.56 | +19.43% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.13 | +298.23% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $2.44 | +1,129.51% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.20 | +1,566.67% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $8.67 | +107.61% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $2.57 | +872.76% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $6.59 | -73.42% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $24.35 | -17.86% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.69 | -44.24% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $9.00 | +2,122.22% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.81 | +196.36% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.44 | +4,081.18% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.47 | +628.74% | 3 | Apr 7, 2020 |
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $18.37
Upside: +112.30%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $29.48
Upside: +73.00%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $16.80
Upside: +7.14%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $32.94
Upside: +60.90%
Kymera Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $81.32
Upside: +47.57%
Nurix Therapeutics
Dec 10, 2025
Maintains: Outperform
Price Target: $24 → $30
Current: $19.30
Upside: +55.44%
Revolution Medicines
Oct 21, 2025
Initiates: Outperform
Price Target: $90
Current: $80.75
Upside: +11.46%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $26.38
Upside: +81.96%
Apogee Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $77.32
Upside: +35.80%
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.14
Upside: +133.64%
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $4.39
Upside: +13.90%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.85
Upside: +110.53%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $18.31
Upside: +145.77%
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $96.92
Upside: -13.33%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $124.70
Upside: -11.79%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $46.24
Upside: -17.82%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $21.03
Upside: -28.67%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $68.87
Upside: -23.04%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $3.17
Upside: +215.46%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.32
Upside: +1,339.39%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.22
Upside: +85.91%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.59
Upside: +479.15%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $16.87
Upside: +113.40%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $9.45
Upside: +323.28%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.56
Upside: +19.43%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.13
Upside: +298.23%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $2.44
Upside: +1,129.51%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.20
Upside: +1,566.67%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $8.67
Upside: +107.61%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $2.57
Upside: +872.76%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $6.59
Upside: -73.42%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $24.35
Upside: -17.86%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.69
Upside: -44.24%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $9.00
Upside: +2,122.22%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $11.81
Upside: +196.36%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.44
Upside: +4,081.18%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.47
Upside: +628.74%